Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus George L. Bakris, MD Mayo Clinic.

Slides:

Advertisements

Similar presentations

Clinical Pharmacology, Uses, and Adverse Reactions of Iodinated Contrast Agents: A Primer for the Non-radiologist Jeffrey J. Pasternak, MD, Eric E. Williamson,

Advertisements

My Treatment Approach to Hairy Cell Leukemia Rahul R. Naik, MD, Alan Saven, MD Mayo Clinic Proceedings Volume 87, Issue 1, Pages (January 2012) DOI:

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved.

Hypertension treatment guidelines from the United Kingdom’s National Institute for Health and Care Excellence. Guidelines identify angiotensin-converting.

Rethinking Cocaine-Associated Chest Pain and Acute Coronary Syndromes

Robert C. Stanton, MD American Journal of Kidney Diseases

Managing Cancer Pain: Basic Principles and Invasive Treatments

Isolated Systolic Hypertension: An Update After SPRINT

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Vitamin D Insufficiency

J. Eric Ahlskog, PhD, MD Mayo Clinic Proceedings

Evaluation of Proteinuria

Robert M. Jacobson, MD, George J. Isham, MD, MS, Lila J

Jean L. Chan, MD, Martin J. Abrahamson, MD Mayo Clinic Proceedings

Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene? Sumeet Gupta, MPharm, PhD,

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

William L. Lanier, MD Mayo Clinic Proceedings

Diagnosis and Management of Chronic Kidney Disease

Charles R. Harper, MD, Terry A. Jacobson, MD Mayo Clinic Proceedings

Thinking Beyond New Clinical Guidelines: Update in Hypertension

Sumana Narasimhan, MD, Ruth S. Weinstock, MD, PhD

Can Vitamin D Deficiency Break Your Heart?

Step Care Therapy for Hypertension in Diabetic Patients

Corticosteroids in the Treatment of Alcohol-Induced Rhabdomyolysis

George Dailey, MD Mayo Clinic Proceedings

Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks Sripal Bangalore, MD, MHA, Gbenga Ogedegbe,

Vahab Fatourechi, M. D. , Frank P. Kennedy, M. D. , Robert A. Rizza, M

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

Palliative Care and Hospice Programs

Membranous nephropathy: When and how to treat

Correction to Lancet Diabetes Endocrinol 2015; 3: 263–74

Gerry H. Tan, M.D., Roger L. Nelson, M.D. Mayo Clinic Proceedings

Manish M. Sood, MD, Amy R. Sood, Robert Richardson, MD

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Correction to Lancet Diabetes Endocrinol 2015; 3: 263–74

Medical management of osteoarthritis

Robert C. Stanton, MD American Journal of Kidney Diseases

Steven J. Rosansky, Richard J. Glassock Kidney International

Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S

MIGUEL A. VALDOVINOS, M. D. , MICHAEL CAMILLERI, M. D. , BRUCE R

Volume 72, Issue 12, Pages (December 2007)

Refurbishing Mayo Clinic Proceedings:

Volume 361, Issue 9352, Pages (January 2003)

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Effect of Spironolactone on Physical Performance in Older People with Self-reported Physical Disability Louise A. Burton, MD, Deepa Sumukadas, MD, Miles.

The future of renoprotection: Frustration and promises

Managing Blood Pressure

Diabetic Mastopathy Mayo Clinic Proceedings

Isolated Systolic Hypertension: An Update After SPRINT

Rethinking Cocaine-Associated Chest Pain and Acute Coronary Syndromes

Craig S. Stump, MD, PhD, Marc T. Hamilton, PhD, James R. Sowers, MD

Serial Measurement of Serum Tryptase in Angiotensin-Converting Enzyme Inhibitor- Associated Angioedema Kevin R. Regner, MD, Douglas L. Riegert-Johnson,

Medical Treatment of Overactive Bladder: In Response

Volume 73, Issue 5, Pages (March 2008)

Mantle Cell Involvement of the Spleen

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

Preoperative Smoking Cessation: The Role of the Primary Care Provider

Medical Student Distress: Causes, Consequences, and Proposed Solutions

Surviving Heart Failure: Robert L. Frye Lecture

Managing Cancer Pain: Basic Principles and Invasive Treatments

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

The Obesity Paradox: Perception vs Knowledge

Diagnosis and Management of Headache in Older Adults

β-Blocker Use for the Stages of Heart Failure

Acute and Chronic Seizures in Patients Older Than 60 Years

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Fig. 3: Possible algorithm for controlling blood pressure in diabetic patients with microalbuminuria. [This algorithm is based on the opinions and practice.

Presentation transcript:

Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus George L. Bakris, MD Mayo Clinic Proceedings Volume 86, Issue 5, Pages 444-456 (May 2011) DOI: 10.4065/mcp.2010.0713 Copyright © 2011 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE A suggested approach to achieve blood pressure goal in patients with diabetes. An estimated glomerular filtration rate (eGFR) of ≥50 mL/min/1.73 m2 generally responds well to thiazide diuretics. Chlorthalidone is the suggested thiazide-like diuretic because it is the diuretic used in clinical trials and forms the basis for the cardiovascular outcomes data. Vasodilating β-blockers have a better tolerability profile and fewer metabolic consequences compared with older agents such as atenolol. ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CCB = calcium channel blocker. From J Am Soc Hypertens,54 with permission from Elsevier. Mayo Clinic Proceedings 2011 86, 444-456DOI: (10.4065/mcp.2010.0713) Copyright © 2011 Mayo Foundation for Medical Education and Research Terms and Conditions